An overview of CAR T-cell clinical trial activity to 2021

TY - JOUR

T1 - An overview of CAR T-cell clinical trial activity to 2021

AU - Adami, Antonella

AU - Maher, John

N1 - Funding Information: This work was supported by Leucid Bio, Breast Cancer Now, (2018JulPR1104), the British Lung Foundation, (MESOUK18-2 INT 1), the Wellcome Trust (104802/Z/14/Z), the Jon Moulton Charity Trust, the Medical Research Council (MR/R001936/1) Publisher Copyright: © 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Immunology.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types.

AB - Immunotherapy of cancer using chimeric antigen receptor-engineered T-cells has transformed the management of selected haematological malignancies, triggering intense clinical trial activity in this arena. This article summarises trial activity that has been published to date across the spectrum of haematological and solid tumour types.

KW - cancer

KW - CAR T-cell

KW - clinical trials

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85117205463&partnerID=8YFLogxK

U2 - 10.1093/immadv/ltab004

DO - 10.1093/immadv/ltab004

M3 - Review article

AN - SCOPUS:85117205463

SN - 2732-4303

VL - 1

JO - Immunotherapy advances

JF - Immunotherapy advances

IS - 1

M1 - ltab004

ER -